Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
75% alcohol is a topical solution utilized as a placebo control in clinical research evaluating treatments for chemotherapy-induced peripheral neuropathy (CIPN). In a specific Phase 1/2 clinical trial led by investigator Han Xi Zhao, this solution serves as the vehicle-matched comparator for Epigallocatechin-3-Gallate (EGCG) in cancer patients experiencing taxane-induced peripheral neuropathy (TIPN). While ethanol is widely recognized for its antiseptic properties and use as a solvent, its application in this context is strictly as a control to determine the safety and therapeutic efficacy of the active EGCG intervention applied topically to the skin of patients exhibiting neurotoxicity symptoms from paclitaxel-related chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 75% alcohol.